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OBJECTIVE: The aim of this clinical trial was to evaluate the effectiveness of using lyophilised porcine
skin (Xenoderm) compared with 1% silver sulfadiazine (SSD) in partial-thickness burns with regard 
to wound infection, length of hospital stay, number of dressings and doses of analgesics used (oral and
injection).
METHODS: A total of 78 burns patients were included in this randomised study; their burns were caused
by scalds or flames. They had second degree burns and had a burn area of 10–60% of total body surface
area (TBSA). Thirty-seven patients were treated with daily washing, followed by topical application of
SSD dressing (the SSD group) and 39 with a biological dressing, i.e. Xenoderm (the Xenoderm group).
The differences were evaluated using unpaired Student’s t-test, Mann-Whitney U test and Chi-square test.
RESULTS: There were no significant differences between the two groups with respect to age, gender,
TBSA, cause of burn, and thickness of the burn or burn site. But there were significant differences regarding
degree of wound infection, length of hospital stay, number of used dressings and given doses of analgesics.
CONCLUSION: Xenoderm seems to be more effective than SSD dressing in terms of pain control, degree
of wound infection, used wound dressings and length of hospital stay for partial-thickness burns.
Prospective randomised studies are now necessary to compare possible reductions in the use of split thick-
ness skin grafts and re-epithelialisation times. [Asian J Surg 2009;32(4):234–9]
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Introduction
Burns have always been a tragedy for man. It has signifi-
cant morbidity and, often, significant mortality.1–3 For
many years, partial-thickness burns have been treated 
by daily washing and cleaning of the wound, followed by
a topical application of antimicrobial cream. However,
the pain suffered and impaired wound healing remain
problems to be addressed.4 Superficial partial-thickness
burns (2nd A degree) often heal in 3 weeks, whereas deep
partial-thickness burns (2nd B degree) and full-thickness
burns (3rd degree), which can be treated by early excision
and grafting, take several weeks to heal.3,5 It is agreed that
the best way to treat deep partial-thickness burns and 3rd
degree burns is early dermabrasion, or escharectomy, fol-
lowed by coverage with skin graft.6
Few studies have compared the effectiveness of biolog-
ical dressings in partial-thickness burns.3,7–9 Allograft, 
synthetic and biological dressings are an integral part of
modern burns care. Today, lyophilised porcine dermis 
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(i.e. a xenograft) has gained acceptance as a temporary
dressing10–12 and is considered an alternative to antimi-
crobial dressings.3,10,11
Xenoderm is a new product derived from lyophilised
porcine dermis. The advantages of lyophilised porcine
skin are its greater adherence to wounds (3–5 weeks),
decrease in pain, evaporative water, heat loss, protein loss,
electrolyte loss, and lower hospital costs.9,10,12–14 In addition
to these, the skin can heal faster, with less scar formation,
and fewer infections.10,14,15 On the other hand, the disad-
vantages of Xenoderm are a theoretical risk of zoonosis
and ethical/religious issues.14,16 Up to now, few descrip-
tive studies have been conducted regarding lyophilised
porcine skin (Xenoderm) in developing countries.16
For many decades, 1% silver sulfadiazine (SSD) has
been used to treat burns and chronic wounds. Topical 
silver cream has a broad spectrum of antimicrobial activ-
ity, low development of bacterial resistance, few adverse
reactions and a low risk of systemic toxicity. However, it
requires frequent application, is care intensive to apply
and remove, and is sometimes painful.3,17
Unfortunately, nowadays many patients with deep
partial-thickness burns (2nd B degree) are treated by daily
washing and SSD dressing in many burns centres in
developing countries. Although recent studies have sup-
ported the application of biological dressings in develop-
ing and Islamic countries, their application is still not
common. The aim of this clinical trial was to evaluate 
the effectiveness of Xenoderm compared with SSD in 
partial-thickness burns with regard to wound infection,
length of hospital stay, number of dressings and doses of
analgesics used (whether oral or injection).
Patients and Methods
In this prospective randomised clinical trial, 78 burns
patients of Shafieeh Hospital in Zanjan (Iran) were inves-
tigated between March 2006 and November 2007. These
patients with partial-thickness burns who entered the
study had a burn area of 10–60% of total body surface 
area (TBSA) caused by scalding or flames. Patients who
had 3rd degree burns (contact burn and others), already
present infection, contaminated wounds (with chemical
or faecal material, or soil), comorbid diseases, fractures,
neurological injury or who were pregnant were excluded
from the study. The depth of burn was very important for
surveillance and management planning, thus all patients
in this study had 2nd degree burns. Informed consent was
obtained from all patients before they were included in
the study. The patients were randomly divided into two
groups consecutively. The first group (i.e. the SSD group)
was treated daily with washing and cleaning, followed 
by topical application of 1% SSD dressing. The second
group (i.e. the Xenoderm group) was treated with the bio-
logical dressing, Xenoderm, a new product of lyophilised
pig skin manufactured by Medical Biomaterial Products
(Berlin, Germany).
In the Xenoderm group, Xenoderm was prepared in
normal saline solution. Then, after tangential excision or
dermabrasion of the burned area, with a dermatome and
rinsing the wound with normal saline, Xenoderm was
placed on the wound by the surgeon and fixed in place
using a suture, dressing, or bandage. All patients received
cefazolin (antibiotic) prophylaxis. Afterwards, the burned
region was immobilised by a splint if necessary. Twenty-
four hours after the surgery, the dressing was removed.
Following this process, after 2–5 weeks Xenoderm was
sloughed spontaneously.
The discharge criteria for both groups of patients
were: the ability to tolerate dressing changes, using only
oral pain medications and the caregiver’s ability to per-
form necessary dressing changes.
All data, including demographics, mechanisms of in-
jury, depth of burns, burn area (percentage of TBSA),
location of burns, length of hospital stay, doses of anal-
gesics given (whether oral or injection, the number of
dressings used, intravenous (IV) fluid administration
(before oral intake by patients), inhalation injury (facial
burns, mucosal oedema and wheezing), wound infection
(secretion of pus) and mortality, were measured by the
physicians and general surgeons of the Burns Depart-
ment of Ayatollah-Mousavi Hospital. Significant differ-
ences were evaluated using the unpaired Student’s t test,
Mann-Whitney U test and Chi-square test. A p value of
less than 0.05 was deemed to be significant. All analyses
were performed using SPSS 11.5 (SPSS Inc., Chicago, IL,
USA). Finally, our study was approved by the Ethics
Committee of Zanjan University of Medical Sciences.
Results
A total of 78 burns patients were randomly divided into
two groups. Two patients in the SSD group left the hos-
pital 2 days after admission and, consequently, were
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excluded from the study. So, 37 patients were in the SSD
group and 39 in the Xenoderm group. There were no 
significant differences between the two groups with
respect to age, gender, % TBSA, cause of burn, burn thick-
ness or burn site (Table 1). In the SSD and Xenoderm
groups, 81.1% and 94.9% of the patients, respectively, were
admitted on the same day on which they were burned.
The mean duration from being burned up to using
Xenoderm was 1.77 ± 0.93 days. Thirty (76.9%) patients
underwent surgery and were covered with Xenoderm
within the first 48 hours.
Inhalation injuries (respiratory burns) in the SSD
group were lower than in the Xenoderm group. The most
commonly burned areas were the upper limbs, lower
limbs and face in both groups. Neck and genital region
burns were more common in the Xenoderm group than
in the SSD group (13 vs. 7 and 8 vs. 1 respectively) (Table 1).
There were significant differences regarding degree 
of wound infection, length of hospital stay, number of
used dressings and given doses of analgesics. Other com-
parators did not show any significant difference between
the two groups (Table 2).
There were wound infections in two (5.1%) patients 
in the Xenoderm group and in 12 (32.4%) patients in the
SSD group during their hospital stays. The rate of infec-
tion for neck wounds was higher than for other parts of
the body in both groups. Follow-up 5 weeks later showed
that the total wound infection rates in the Xenoderm and
SSD groups were 17.9% (7 patients) and 40.5% (15 patients)
respectively (p = 0.03). These patients were treated with
split thickness skin grafts (STSG). Fifteen (38.4%) patients
with a mean burn area of 14.7% TBSA in the SSD group
and 31 (83.7%) patients with a mean burn area of 17.2%
TBSA in the Xenoderm group were discharged from the
hospital in less than 1 week.
In the Xenoderm group, the mean number of dress-
ings used between the initial time of referral to hospital
and surgery was 1.97 (range, 1–4). After using Xenoderm,
Table 1. Patients’ demographic characteristics
SSD group (n= 37) Xenoderm group (n= 39) p
Male 24 (64.9%) 26 (66.7%) NS
Female 13 (35.1%) 13 (33.3%) NS
Mean age, yr (range) 24.9 (1–67) 18.9 (1–74) NS
Mechanism of injury NS
Scalding 15 (40.5%) 20 (51.3%)
Flames 22 (59.5%) 19 (48.7%)
Inhalation injury 6 (16.2%) 11 (28.2%)
Mean burn area, % TBSA (range) 16.4% (10–54%) 17.6% (10–45%) NS
Depth of burn NS
2nd A degree 9 (24.3%) 6 (15.4%)
2nd A & 2nd B degree 19 (51.4%) 21 (53.8%)
2nd & 3rd degree 9 (24.3%) 12 (30.8%)
Location of burn
Face 15 (40.5%) 19 (48.7%) NS
Neck 7 (18.9%) 13 (33.3%) NS
Body 12 (32.4%) 16 (41%) NS
Upper limbs 23 (62.1%) 20 (51.2%) NS
Lower limbs 18 (48.6%) 25 (64.1%) NS
Genital area 1 (2.7%) 8 (20.5%) –
Total wound infection 15 (40.5%) 7 (17.9%) –
Zoonosis – 2 (5.1%) –
SSD = 1% silver sulfadiazine dressing; TBSA = total body surface area; NS = non significant.
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this number was 1.26 (range, 0–25). In the Xenoderm
group, 23 (58.9%) patients did not use any other dress-
ings, 14 (35.8%) patients used only one dressing, and 
two patients used more than 10 dressings after using
Xenoderm because of wound infection. In the SSD 
group, 15 patients used dressings more than ten times.
In the SSD and Xenoderm groups, 32.4% and 38.4% of
the patients, respectively, did not use any injected anal-
gesics. The results of taking oral analgesics indicated 
that 62% of patients in the SSD group and 23% of patients
in the Xenoderm group used more than six doses. The
median number of analgesics were seven and three for 
the SSD group and Xenoderm group respectively.
Detaching Xenoderm from the burn site began from
the 2nd week and continued up to the 5th week (Figures
1–3). However, if the Xenoderm did not detach after 
5 weeks, it was considered to indicate the presence of
zoonosis (the Xenoderm was not rejected by the recipient
site). This occurred in two patients with very deep partial-
thickness burns. The most common sites were the legs in
this case. These patients were treated by excision of the
Xenoderm and grafting STSG.
Discussion
The present study supports the hypothesis that appli-
cation of Xenoderm, as compared to SSD, leads to a
reduction in wound infection rate, length of hospital stay,
dressing changes and use of oral analgesics.
The results showed us that in the SSD group, the
wound infection rate (during the hospital stay plus the 
5-week follow-up) was greater than in the Xenoderm
group (40.5% vs. 17.9%). Most of the infections in the
Xenoderm group occurred in patients who had suffered
burns in the “wrinkly” parts of their bodies, such as neck,
axilla and groin. This caused the Xenoderm to detach
from the burn site earlier than expected, leading to 
infection. Joining Xenoderm to the wound led to a 
Table 2. Effect of treatment on various clinical parameters in patients
Variable Group n Mean (SD) Median p
Age 1% Silver sulfadiazine 37 24.9 (18.7) 23 0.09
Xenoderm 39 18.9 (20.1) 15
Burn area (% TBSA) 1% Silver sulfadiazine 37 16.4 (9.1) 13 0.43
1% Xenoderm 39 17.7 (8.3) 16
Number of dressings 1% Silver sulfadiazine 37 10.9 (9.2) 8 0.0005
Xenoderm 39 3.2 (4.4) 2
Number of analgesics (IV) 1% Silver sulfadiazine 37 4.08 (12.2) 2 0.02
Xenoderm 39 0.92 (0.9) 1
Number of analgesics (oral) 1% Silver sulfadiazine 37 11.5 (15.5) 7 0.0005
Xenoderm 39 4.5 (5.3) 3
First hospital stay (d) 1% Silver sulfadiazine 37 11.2 (9.3) 8 0.003
Xenoderm 39 6.3 (4.6) 5
IV serum before oral intake 1% Silver sulfadiazine 37 4.9 (6.2) 2 0.98
Xenoderm 39 3.7 (3.7) 2
SD = standard deviation; TBSA = total body surface area; IV = intravenous.
Figure 1. Attachment and detachment of Xenoderm on the 18th
day of Xenoderm usage.
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restriction of potential “necrotic space” and a prevention
of hematoma and seroma that could otherwise cause
infection.11 Hence, Xenoderm acts as a physical barrier
against excessive bacterial growth.18–20 Gravante et al
reported that a biological dressing guarantees a tempo-
rary barrier function, avoiding vapour loss whilst reduc-
ing bacterial invasion (the infection rate decreased from
29.5% to 10%).21 Also, some studies have reported that
when using SSD, there were more wound infections than
when using a biological dressing.8,21,22 As you can see in
our study, the infection rate during hospital stay was
32.4% in the SSD group versus 5.1% in the Xenoderm
group. These results are not much different from
Gravante et al’s study. One of the reasons for the increase
in infection rate in patients after hospital discharge is fur-
ther contamination. The other is the exact record of small
wounds in the wrinkly parts of the body.
Figure 2. Attachment and detachment of Xenoderm on the 24th
day of Xenoderm usage.
Figure 3. Attachment and detachment of Xenoderm on the 52nd
day of Xenoderm usage.
The length of hospital stay in the SSD group was
longer than in the Xenoderm group; 83.7% of the patients
in the Xenoderm group (with a mean burn area of 
17.2% TBSA) were discharged from hospital in less than 
1 week. This short hospital stay was due to faster re-
epithelialisation, reduction of wound infection and fewer
wound dressing changes. Hosseini et al reported that the
mean length of hospital stay for 2nd degree burns (with 
a mean burn area of 16.8% TBSA) which were treated 
with Xenoderm dressing was 6.45 ± 5.51 days.16 Other
studies have reported that using biological or synthetic
dressings can reduce the length of hospital stay in 2nd
degree burns.1,7,8,21,23,24 This reduces costs for patients
and allows the hospital beds to be used for other trauma
patients.
The mean number of dressings used in the SSD group
was greater than in the Xenoderm group. Twenty-three
(58.9%) patients in the Xenoderm group did not use
dressings after using Xenoderm. However, in cases of
infection, the number of dressings increased. Daily dress-
ing changes are very painful.12 Kumar et al suggested that
fewer dressings would be required in partial-thickness
burns in children if synthetic dressings were used.7 Other
studies have reported that pig skin has pain-relieving
effects on burns patients.11,13,16,21,25 Therefore, with fewer
dressing changes for burns, patients would be more satis-
fied and more comfortable during treatment, and these
good results would be enhanced by less use of analgesics.
Finally, our results showed that there was a significant
difference in the number of oral analgesics used between
the two groups. It was found that 62% of the patients in
the SSD group and 23% of the patients in the Xenoderm
group needed not more than six doses of oral analgesics.
The low use of oral analgesics in the Xenoderm group
may be due to the fact that Xenoderm adheres to the
wounds and decreases pain, infection rate and number of
dressings used.7,9,10,14,26 This has been well documented
in previous studies.27,28
Conclusion
Our study suggests that using a biological dressing
(Xenoderm) can be a good and feasible approach in 
treating partial-thickness burns. Based on our clinical
experience, Xenoderm seems to be more effective 
than SSD in terms of pain control, wound infection,
number of wound dressings and length of hospital stay 
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in partial-thickness burns. Prospective randomised stud-
ies are now necessary to determine the possibility of
reducing STSG use and assessing re-epithelialisation
time.
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